Plain-English translation of NCT06920433 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing a new treatment called universal allogeneic CAR T-cell therapy targeting CD19 and BCMA, which is designed to help people with severe, treatment-resistant lupus—especially lupus affecting the kidneys. The treatment involves modifying immune cells to recognize and control the cells driving the disease. This is an early-stage study to see if the medication is safe and whether it helps reduce lupus symptoms and kidney damage.
Standard lupus treatments stop working for some patients, leaving them with few options and ongoing organ damage, particularly in the kidneys. This trial is exploring whether this new type of cell therapy could help people whose disease hasn't responded to conventional medications.
You likely qualify if…
You likely don't qualify if…
You would receive chemotherapy medication to prepare your immune system, followed by a single infusion of the new immune cells through an IV. You would then be monitored closely with blood tests and clinic visits over at least 90 days to check for safety and how well the treatment works. The study will track your lupus symptoms, kidney function, and any side effects during this period.
AI-generated summary from trial data · Jun 2, 2026 · Not medical advice
China
Phase
Safety & dosing
Sponsor
Zhejiang University
Collaborators
Shanghai Xiniao Biotech Co., Ltd.
Enrollment target
~18 participants
Started
April 2025
Primary completion
April 2026
This trial's estimated completion date has passed — the record may not be fully up to date.
Age range
18 Years and older
Last updated on clinicaltrials.gov in May 2025.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
He Huang
Zhejiang University
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.